Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Pulmonary Drug Delivery Systems Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024


 

Available formats:    

StumbleUponEmail

Global Pulmonary Drug Delivery Systems Market: By Product Type (Metered Dose Inhaler, Nebulizer, Dry Powder Inhaler), By Technology (Manually Operated Inhalers, Digitally Operated Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

 

Global pulmonary drug delivery systems market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.

 

Market Outline: Pulmonary Drug Delivery Systems Market

Pulmonary drug delivery systems helps to treat diseases such as asthma, cystic fibrosis. The pulmonary route is used in the treatment of various respiratory disorders. The pulmonary drug delivery is gaining popularity owing to its target specificity. The pulmonary drug delivery system delivers the medication thorough the respiratory tract. It is majorly used in the treatment of the conditions such as delivery of locally acting drugs directly to the sites of action.

Market Dynamics: Pulmonary Drug Delivery Systems Market

Increase in the prevalence of various chronic disease such as chronic pulmonary disease, tuberculosis, and bronchitis are expected to fuel the growth of pulmonary drug delivery systems market. The preference of the non-invasive techniques are witnessing to the growth of market. The minimum dosage requirement is another factor, which creates demand for pulmonary drug delivery systems market. The technological advancements, growing support from the government and non-government organizations, increasing awareness and rising funds are expected to anticipate the growth of the market. However, the government regulatory issues in the approval of the product would hamper the growth of pulmonary drug delivery systems market.

Market Scope: Pulmonary Drug Delivery Systems Market

Pulmonary drug delivery systems market is segmented based on the product type, application, and distribution channel

Based on the product type, the market is segmented into the following:

  • Metered Dose Inhaler
    • Manually-Actuated Pressurized Inhaler
    • Breath-Actuated Pressurized Inhaler
  • Nebulizer
    • Ultrasonic Wave Nebulizers
    • Vibrating Mesh Nebulizers
    • Jet Nebulizers
  • Dry Powder Inhaler
    • Single-Dose Inhalers
    • Multi-Dose Inhalers

Based on the technology, the market is segmented into the following:

  • Manually Operated Inhalers
  • Digitally Operated Inhalers

Based on the disease indication, the market is segmented into the following:

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Arterial Hypertension
  • Others

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Analysis:  Pulmonary Drug Delivery Systems Market

Geographically, global pulmonary drug delivery systems market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America pulmonary drug delivery systems market is anticipated to expand at robust growth rates due to increase in prevalence of respiratory disorders. The surge in awareness about the modern treatment options and its adoption is expected to create healthy growth opportunities over the forecast period. As per World Health Organization (WHO) statistics, smoking is estimated to cause 71% of the lung cancer deaths and 42% of the chronic respiratory diseases worldwide. Out of the six regions of WHO, Europe was accounted for highest prevalence for smoking i.e., 29 per cent in 2008. The Europe pulmonary drug delivery systems market is expected to show a significant growth over the forecasted period. The Asia Pacific pulmonary drug delivery systems market is predicted to show tremendous growth in the emerging countries such as India and China owing to rising population coupled with increasing prevalence of respiratory disorders.

Competition Assessment: Pulmonary Drug Delivery Systems Market

Some of the players in the global pulmonary drug delivery systems market include:

  • Sunovion Pharmaceuticals Inc. (U.S)
  • AstraZeneca plc (U.K)
  • Omron Corporation (Japan)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline (U.K)
  • 3M (U.S)
  • Boehringer Ingelheim GmbH (Germany)

Notable Market Developments: Pulmonary Drug Delivery Systems Market

  • In December 2017, Sunovion receives the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution, also known as SUN-101/eFlow, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

 

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Sunovion Pharmaceuticals Inc. (U.S)
  • AstraZeneca plc (U.K)
  • Omron Corporation (Japan)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline (U.K)
  • 3M (U.S)
  • Boehringer Ingelheim GmbH (Germany)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553